Supplementary Table Demographic and clinical features of participants

|  |  |  |
| --- | --- | --- |
|  | HIV-1 infected patients(n=75) | HIV-negative participants(n=55) |
| Age (years), median(IQR) | 37.1 (30.8-46.5) | 35.2 (28.7-45.6) |
| Gender: male/female, no. | 40/35 | 30/25 |
| BMI , median(IQR) | 21.3 (20.1 -23.6) | 21.8 (20.9-22.7) |
| Years since diagnosis, median(IQR) | 2.4 (1.9-3.3) | N/A |
| Mode of transmission: MSM/HS/unknown, no. | 21/16/38 | N/A |
| HAART status |  |  |
| Untreated (n=12) | N/A | N/A |
| Treated (n=63), months of treatment, median(IQR) | 14.17 (5.78 -36.50) | N/A |
| CD4+ T-cell count (cells/μL), median(IQR) | 280.3 (180.7 -544.8) | N/A |
| CD4+ T-cell (%), median(IQR) | 19.6 (13.4 -24.1) | N/A |
| CD8+ T-cell count (cells/μL), median(IQR) | 731.1 (514.5-980.1) | N/A |
| CD8+ T-cell (%), median(IQR) | 46.9 (37.9 -55.0) | N/A |
| Plasma HIV RNA  |  |  |
| <40 copies/mL (n=36) | N/A | N/A |
| >40 copies/mL (n=27), median(IQR) | 25700 (5090-74500) | N/A |
| unavailable (n=12) | N/A | N/A |
| Microbial translocation markers , median(IQR)  |  |  |
| LPS (ng/L), median(IQR) | 555.6 (466.5-663.0) | 573.5 (410.0-755.7) |
| LBP (ug/L), median(IQR) | 44.6 (30.4-55.3) | 39.5 (29.2-55.9) |
| sCD14 (ug/L), median(IQR) | 51.6 (40.8-60.9) | 52.9 (42.0-68.5) |
| \*MBP/MBL (ug/L), median(IQR) | 23.2 (16.4-32.3) | 26.3 (22.3-38.9) |
| \*TNF-α (ng/L), median(IQR) | 356.1 (248.5-471.5) | 225.3 (123.9-311.9) |
| IL-6 (ng/L), median(IQR) | 24.4 (21.5-30.5) | 20.6 (15.8-32.8) |
| \*IL-1 β (ng/L), median(IQR) | 63.8 (54.6-77.9) | 71.4 (61.6-95.4) |
| \*IL-10 (ng/L), median(IQR) | 392.0 (169.8-587.2) | 457.2 (380.5-722.8) |
| \*IL-22 (ng/L), median(IQR) | 28.3 (22.1-39.6) | 20.4 (11.0-32.0) |
| IL-17 (ng/L), median(IQR) | 20.4 (16.7-24.9) | 19.4 (15.8-27.7) |

\*, which soluble biomarkers levels observed to be significantly differed between HIV+ and HIV- groups, *P*<0.05